Cargando…

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Fedorov, Kateryna, Feldman, Eric, Saunthararajah, Yogen, Shastri, Aditi, Kornblum, Noah, Sica, Alejandro, Shah, Nishi, Konopleva, Marina, Gritsman, Kira, Braunschweig, Ira, Levitz, David, Cooper, Dennis, Comas, Monica, Pradhan, Kith, Verma, Amit, Mantzaris, Ioannis, Goldfinger, Mendel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429033/ http://dx.doi.org/10.1097/01.HS9.0000969004.90768.e2

Ejemplares similares

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
por: Mantzaris, Ioannis, et al.
Publicado: (2023)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
por: Rabinovich, Emma, et al.
Publicado: (2021)

Autologous stem cell transplantation in an older adult population
por: Fedorov, Kateryna, et al.
Publicado: (2022)

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions
por: Zavras, Phaedon D., et al.
Publicado: (2021)

Primary central nervous system lymphoma: treatment access and outcomes in HIV positive patients in a minority rich cohort
por: Narvel, Hiba, et al.
Publicado: (2023)

Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort
por: Shapiro, Lauren C, et al.
Publicado: (2021)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
por: Abbasi, Ahmed, et al.
Publicado: (2020)

High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012)

Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction
por: Uchida, Naoya, et al.
Publicado: (2014)

A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia
por: Zawit, Misam, et al.
Publicado: (2021)

Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion
por: Chilakala, Sujatha, et al.
Publicado: (2019)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF
por: Ibanez, Vinzon, et al.
Publicado: (2023)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
por: Lavelle, Donald, et al.
Publicado: (2010)

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
por: Negrotto, Soledad, et al.
Publicado: (2011)

Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
por: Klocke, Heather, et al.
Publicado: (2020)

FRI645 A Case Of Diabetic Ketoacidosis After Initiation Of Decitabine And Venetoclax Chemotherapy
por: Maini, Rohan, et al.
Publicado: (2023)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Targeting sickle cell disease root-cause pathophysiology with small molecules
por: Saunthararajah, Yogen
Publicado: (2019)

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation
por: Saunthararajah, Yogen
Publicado: (2020)

Extended experience with a non‐cytotoxic DNMT1‐targeting regimen of decitabine to treat myeloid malignancies
por: Awada, Hassan, et al.
Publicado: (2019)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
por: Gu, Xiaorong, et al.
Publicado: (2020)

Venetoclax resistance: mechanistic insights and future strategies
por: Ong, Faustine, et al.
Publicado: (2022)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
por: Maravalle, Denise, et al.
Publicado: (2022)

LC–MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study
por: Alnasser, Abdulaziz I., et al.
Publicado: (2023)

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE
por: Saunthararajah, Y., et al.
Publicado: (2023)

Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
por: D'Aiello, Angelica, et al.
Publicado: (2022)

Sinusoidal Obstruction Syndrome (SOS) in Multiple Myeloma with Renal Failure
por: Shah, Urvi A., et al.
Publicado: (2018)

Séminaire Bourbaki : exposés 507–524
por: Dold, A, et al.
Publicado: (1979)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_72q1q3bjh265dm87ros8oboja8